

Press communication Lund, Sweden, August 8, 2023 This is a translation of the Swedish press release published 2023-08-08

Neola Medicals trademark has been registered in the U.S.

Neola Medical AB (publ) announces today that the company's trademark, Neola®, has been registered in the U.S, the company's most important market. The new trademark registration mean that the company strengthens its competitiveness before the launch in the U.S of the company's medical device for lung monitoring of preterm born infants.

"We are glad that our trademark Neola® now is registered in the U.S, our largest and most important market. With this registration we secure our position as an innovative and respected brand within intensive care of preterm born infants. We continue to build our brand as a symbol for groundbreaking medical technology with high quality and trust that focuses on the care of our smallest patients.", says Hanna Sjöström, CEO at Neola Medical.

The company's trademark, Neola®, has been registered in the U.S. for class 10 (Medical device) and class 42 (Science and technology services, R&D services). The trademark has already been registered in Europe, Australia, and China. The trademark registration is of great importance before the commercial launch of Neola®, as it strengthens the company's positioning on the international market. Ensuring a strong trademark is an important part of the company's market strategy and the registration of Neola® in the U.S. means that the company has extended its protection on its largest and most important future market.

For further information, contact

Hanna Sjöström, CEO Neola Medical, e-mail: hanna.sjostrom@neolamedical.com

Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants' lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 as a wholly owned subsidiary of Gasporox AB (publ) under the name GPX Medical AB. The company is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.